Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Updates to NCCN SCLC guidelines includes the option of maintenance lurbinectedin 3.2mg/m2 (with primary G-CSF) plus atezolizumab after induction (for patients who have not progressed).
Based on phase III IMforte study that showed improvement in PFS (HR 0.54) and OS (HR 0.73).”
More posts featuring NCCN on OncoDaily.